Unicycive Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Agreements (Details)

Significant Agreements (Details) - USD ($) $ in Thousands							1 Months Ended	9 Months Ended	12 Months Ended
Significant Agreements (Details) - USD ($) $ in Thousands	Apr. 10, 2023	Feb. 01, 2023	Jul. 14, 2022	Jan. 06, 2022	Jul. 13, 2021	Oct. 31, 2017	Sep. 30, 2018	Sep. 30, 2021	Dec. 31, 2025	Dec. 31, 2024	Feb. 28, 2023	Aug. 31, 2022
Significant Agreements [Line Items]
Agreement due payments						$ 1,650
Second clinical trial payment						$ 50
Net sales percentage						2.00%
Common stock valued									$ 45,184	$ 524
Anti-dilution shares of common stock (in Shares)									18,796,272	19,498,672
Revision overall budget				$ 2,900
Research related payments	$ 2,900								$ 2,900
Milestone payments		$ 3,700
Payment amount									$ 4,500
Exclusive license agreement [Member]
Significant Agreements [Line Items]
Agreement due payments						$ 50
Spectrum Agreement [Member]
Significant Agreements [Line Items]
Issued of common shares (in Shares)							31,366
Common stock valued							$ 4
Public market capitalization					$ 50,000		$ 50,000
Research and development expenses								$ 2,200
Sublicense income granted percentage							40.00%
Sublicense income percentage							20.00%
Spectrum Agreement [Member] \| Investment [Member]
Significant Agreements [Line Items]
Interest on ownership							4.00%
Spectrum Agreement [Member] \| Common Stock [Member]
Significant Agreements [Line Items]
Anti-dilution shares of common stock (in Shares)					43,838
Sublicense Development Agreement [Member]
Significant Agreements [Line Items]
Significant payment received											$ 700	$ 1,000
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Sublicense income percentage									20.00%
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Research and development expenses				$ 3,700
Altair Nanomaterials, Inc [Member] \| Spectrum Agreement [Member]
Significant Agreements [Line Items]
Required to pay								200
Altair [Member] \| Spectrum Agreement [Member]
Significant Agreements [Line Items]
Required to pay								$ 4,500
Quotient Sciences Limited [Member]
Significant Agreements [Line Items]
Research related payments									$ 2,900
Inotiv [Member]
Significant Agreements [Line Items]
Payments to related party									2,900
Lee’s Pharmaceutical (HK) Limited [Member]
Significant Agreements [Line Items]
Significant payment received			$ 1,000
Milestone payments			$ 1,000
Lotus International Pte Ltd [Member]
Significant Agreements [Line Items]
Significant payment received		$ 700
Shilpa Medicare Ltd [Member]
Significant Agreements [Line Items]
Payment amount									$ 4,500
Minimum [Member]
Significant Agreements [Line Items]
Royalties percentage			7.00%
Maximum [Member]
Significant Agreements [Line Items]
Royalties percentage			10.00%